Evaluation of Patients Who Have Not Had Success With Zidovudine
Status:
Completed
Trial end date:
1995-05-01
Target enrollment:
Participant gender:
Summary
To determine the relationship of viral susceptibility to zidovudine (AZT) and baseline viral
load (as determined by plasma viremia and quantitative endpoint dilution). To determine the
relationship between viral load and susceptibility during different antiretroviral therapy
strategies. To correlate measures of viral load and short term clinical and laboratory
markers (such as weight, CD4 count, p24 antigenemia, and beta2 microglobulin) on the
different therapy arms.
High-grade resistance to AZT has been detected in HIV isolates from approximately 25 percent
of individuals with AIDS who received AZT for at least 1 year. To elucidate the clinical
significance of in vitro AZT resistance, it is necessary to distinguish between clinical
failure caused by AZT resistance and clinical decompensation caused by other factors.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)